Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Mauger
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novartis
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The study compares Xolair® (omalizumab) to placebo in children with asthma. In the US, Novartis and Genentech work together to develop and co‐promote Xolair. Dr. Mauger reports serving as a paid member of a Novartis Data Monitoring Committee. Although the reported compensation is less than $5,000, our institution reviews financial interest
Controlling and preventing Asthma progression and Severity in Kids (CASK)
PROJECT NARRATIVE Asthma remains one of the most important challenges to pediatric public health in the United States affecting millions of children, and continues to increase in prevalence, causing significant morbidity, mortality, and tremendous financial burden. Prevention of asthma is a pressing, unmet need of utmost priority. This protocol is aimed at the prevention of progression from allergic wheezing to asthma and will address the hypothesis that treatment of high-risk children with allergic sensitization and wheeze with omalizumab (anti-IgE), an intervention directed towards IgE, will alter disease progression as reflected by a reduced current, active diagnosis of asthma 2 years after the completion of therapy.
Filed on September 17, 2018.
Tell us what you know about David Mauger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Mauger”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Mauger | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | AstraZeneca | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.